Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
Anke BarnbrockAnja MörickeDraga BarbaricNeil JonesChrista KoenigReinhard MoserMarius RohdeChristina SalvadorJulia AltenSarah ElitzurAndreas H GrollThomas LehrnbecherPublished in: British journal of haematology (2024)
Pneumocystis jirovecii can cause life-threatening pneumonia (PjP), and patients with haematological malignancies are at high risk of this infection. Prophylactic measures have significantly decreased morbidity and mortality, but there is a paucity of contemporary data on the incidence and clinical course of PjP in well-defined and homogenous patient populations, such as children suffering from acute lymphoblastic leukaemia (ALL). In the multi-international trial AIEOP-BFM ALL2009, PjP was diagnosed in six children (incidence 1/1000) and was associated with insufficient prophylaxis in five of them. Although none of the patients died of PjP, the long-term impact of the infection is unclear.
Keyphrases
- respiratory failure
- clinical trial
- liver failure
- end stage renal disease
- young adults
- risk factors
- study protocol
- ejection fraction
- chronic kidney disease
- newly diagnosed
- phase ii
- phase iii
- emergency department
- peritoneal dialysis
- prognostic factors
- intensive care unit
- aortic dissection
- randomized controlled trial
- extracorporeal membrane oxygenation
- open label
- electronic health record
- machine learning
- big data